Hjem › Inflammatorisk tarmsygdom › Illinois
Inflammatorisk tarmsygdom kliniske forsøg i Illinois
7 studier for Inflammatorisk tarmsygdom søger deltagere på steder i Illinois.
Byer i Illinois
Officiel studietekst (engelsk)
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- Northwestern University, Chicago
- Avicenna Clinical Research - SW Gastroenterology, Oak Lawn
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 30. sep. 2026 · NCT06598943A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- Site 038, Chicago
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 29. sep. 2026 · NCT07012395A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
- Site US-005, Des Plaines
- Site US-007, Glenview
- Site US-020, Gurnee
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 29. sep. 2026 · NCT07845487A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
- Northwest Gastroenterologist, Glenview
RekruttererFase 4
3 Weeks · Kvinder · Opdateret 8. sep. 2026 · NCT07612267A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis
- Rush University Medical Center, Chicago
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 9. jun. 2026 · NCT05579392A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Glenview
- Mirador Therapeutics Selected Site, Gurnee
RekruttererFase 2
Alder 18 til 80 · Alle køn · Opdateret 12. mar. 2026 · NCT07113522The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
- University of Chicago Medical Center, Chicago
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 18 og opefter · Alle køn · Opdateret 4. mar. 2026 · NCT01280825Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.